Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Ann Chomiak

Physician Assistant, Medical Trumbull, CT Physician Assistant

NPI 1669577953 CMS profile 10553033

5520 Park Ave, Trumbull, CT 06611

Open in the dashboard

General payments

$10,315

660 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Ann Chomiak of Trumbull, CT is reported in the CMS Open Payments database as having received $10,315 across 660 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,588 110
2024 General $2,013 124
2023 General $1,690 99
2022 General $2,308 136
2021 General $2,716 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Ann Chomiak
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mary Ann Chomiak were reported at $1,588. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mary Ann Chomiak Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,716 $156 $41–$563 $132
2022 $2,308 $185 $55–$649 $149
2023 $1,690 $199 $58–$717 $160
2024 $2,013 $206 $62–$740 $164
2025 $1,588 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,054 211 payments
  2. Scilex Pharmaceuticals Inc. $1,796 91 payments
  3. AbbVie, Inc. $1,163 58 payments
  4. Collegium Pharmaceutical, Inc. $1,094 83 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $945 43 payments
  6. Pfizer Inc. $517 27 payments
  7. IBSA Pharma Inc. $414 21 payments
  8. RedHill Biopharma Inc. $384 26 payments
  9. TerSera Therapeutics LLC $300 10 payments
  10. Idorsia Pharmaceuticals US Inc $278 16 payments
  11. Other $1,371 74 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,289 654 payments
  2. Education $26 3 payments
  3. Gift $0 3 payments
Products named General payments · program years 2021–2025
  1. RELISTOR Gastroenterology $1,656 169 payments
  2. ZTLido $1,509 78 payments
  3. XTAMPZA $1,032 79 payments
  4. TRINTELLIX $887 41 payments
  5. RELISTOR Gastroenterology $852 84 payments
  6. UBRELVY $827 42 payments
  7. QULIPTA $485 22 payments
  8. Licart $414 21 payments
  9. Movantik $384 26 payments
  10. NURTEC ODT $358 20 payments
  11. Other $2,788 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

7,921

Median for Physician Assistant: 241

Drug cost

$568,798

Median for Physician Assistant: $4,110

Branded share of claims

28.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 48 $105,229
Oxycontin Oxycodone Hcl Brand 135 $56,070
Dermacinrx Lidocan Lidocaine Brand 25 $40,324
Nurtec Odt Rimegepant Sulfate Brand 18 $35,535
Ztlido Lidocaine Brand 83 $32,145
Cyclobenzaprine Hcl Generic 353 $30,392
Oxycodone Hcl Generic 1,481 $28,194
Lidocaine Generic 405 $27,193
Trintellix Vortioxetine Hydrobromide Brand 34 $23,759
Belbuca Buprenorphine Hcl Brand 27 $20,702

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$106,314

Of which drugs: $55

Medicare patients

220

Average age 70

Services billed

2,207

137 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Depression 36%
Ischemic heart disease 31%
Atrial fibrillation 22%
COPD 22%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 16 440 $45
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 124 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $467
$467 48 —
ZTLido
  • Scilex Pharmaceuticals Inc. $463
$463 83 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $247
$247 43 —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $141
$141 34 —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $134
$134 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

660 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record